Dantari

company

About

Developer of a pharmaceutical platform and drugs created for the treatment of the central nervous system.

Details

Last Funding Type
Series A
Last Funding Money Raised
$47M
Industries
Life Science
Founded date
Jan 1, 2018
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
Dantari, Inc.

Developer of a pharmaceutical platform and drugs created for the treatment of the central nervous system. The company's platform and therapies specialize in the research and development of small and large molecule therapeutics across the blood-brain barrier, enabling clients to have rapidly advance therapies to treat the patients and provide meaningful medical improvement in their lives.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$47M
Dantari has raised a total of $47M in funding over 2 rounds. Their latest funding was raised on Dec 8, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 8, 2022 Series A $47M 4 Westlake Village BioPartners Detail
Apr 26, 2021 Funding Round 2 Corner Ventures
Westlake Village BioPartners
Detail

Investors

Number of Lead Investors
Number of Investors
3
4
Dantari is funded by 4 investors. Westlake Village BioPartners and Alexandria Venture Investments are the most recent investors.
Investor Name Lead Investor Funding Round
Westlake Village BioPartners Yes Series A
Alexandria Venture Investments Series A
Caltech Series A
Corner Ventures Series A

Employee Profiles

Number of Employee Profiles
5
Dantari has 5 current employee profiles, including Executive Richard Markus
Executive
Board member
Board member
Board member
Board member